- Wainzua (eplontersen) recommended by CHMP for EU approval for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or 2 polyneuropathy.
Mon Oct 21 07:02:40 -2024 UTC– AstraZeneca’s Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
Transthyretin-Mediated Amyloidosisis characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy. Amyloidosis can involve the heart, central nervous system (CNS), eyes, and kidneys